Skip to main content
Curocell Inc. logo

Curocell Inc. — Investor Relations & Filings

Ticker · 372320 ISIN · KR7372320002 KO Manufacturing
Open in API
Filings indexed 109 across all filing types
Latest filing 2024-11-15 Director's Dealing
Country KR South Korea
Listing KO 372320

About Curocell Inc.

https://curocellbtx.com/

Curocell Inc. is a clinical-stage biotechnology company specializing in the development of Chimeric Antigen Receptor T-cell (CAR-T) therapies. The company focuses on engineering a patient's own immune cells to recognize and eliminate cancer, primarily targeting blood cancers. Curocell's proprietary OVIS™ technology is an immune checkpoint receptor platform designed to enhance the efficacy of CAR-T treatments by overcoming the immunosuppressive tumor microenvironment. The company has advanced its lead candidate, anbalcabtagene autoleucel (Limkato), through Phase 2 clinical trials and operates a state-of-the-art GMP facility for the production of its advanced cell therapies.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service in South Korea. This type of filing is a standard regulatory disclosure for insider trading or changes in share ownership by company directors/executives. Based on the provided definitions, this falls under 'Director's Dealing' (DIRS).
2024-11-15 Korean
분기보고서 (2024.09)
Interim / Quarterly Report Classification · 1% confidence The document is a '분기보고서' (Quarterly Report) for the company '주식회사 큐로셀' (Curocell Inc.) covering the period from January 1, 2024, to September 30, 2024. It contains detailed corporate information, business descriptions, capital changes, and financial structure, which are characteristic of a formal quarterly financial report filed with the Korean regulatory authorities (Financial Supervisory Service/Korea Exchange). 9M 2024
2024-11-13 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (DART system) used by company insiders (executives/directors) to disclose changes in their shareholdings, such as exercising stock options. This falls under the category of 'Director's Dealing' (DIRS).
2024-10-07 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 1% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (Non-Deal Roadshow). It provides details such as the date, location, target audience, and purpose of the meeting. It does not contain the actual presentation slides or financial data, but rather serves as a notification of the event's occurrence. Given the short length and the nature of the announcement, it fits the criteria for a regulatory filing announcement regarding corporate events.
2024-09-26 Korean
반기보고서 (2024.06)
Interim / Quarterly Report Classification · 1% confidence The document is a '반기보고서' (Semi-annual Report) for the company '주식회사 큐로셀' (Curocell Inc.) covering the period from January 1, 2024, to June 30, 2024. It contains detailed financial information, business operations, management discussions, and corporate governance details, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2024
2024-08-13 Korean
투자판단관련주요경영사항(임상시험결과) (안발셀(CRC01)의 제2상 임상시험내 코호트 2A(림프종) CSR 결과)
Regulatory Filings Classification · 1% confidence The document is a formal regulatory filing from a Korean company (Curocell) submitted to the Korea Exchange (KRX). It details the results of a Phase 2 clinical trial (CSR results) for a drug candidate. While it contains clinical data, it is structured as a 'Major Management Matter' (투자판단 관련 주요경영사항) filing, which is the standard format for material disclosures in the Korean market. Since it does not fit into specific categories like 10-K or Earnings Release, and is a formal regulatory disclosure rather than a simple announcement of a report, it falls under the 'Regulatory Filings' category.
2024-05-30 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.